News

(Richmond, BC) – Advanced Cyclotron Systems, Inc. (ACSI), is pleased to announce the release of a new cyclotron: the TR-FLEX. The TR-FLEX will complement ACSI’s current lineup of cyclotrons and provide its customers with a cost effective solution for the production of all common SPECT and PET radioisotopes.
The TR-FLEX cyclotron can be fully customized to the specific needs of the customer. Users may select a range of extracted beam energy from as low as 18 MeV to a maximum energy …

(Richmond, BC) – Advanced Cyclotron Systems, Inc. (ACSI), is pleased to announce that it has signed an agreement for the supply of a TR-24 cyclotron system to be installed at TRIUMF, Canada’s National Laboratory for Particle and Nuclear Physics.
In a ceremony held on May 30th, 2014 at the UBC campus, the Honorable Michelle Rempel, Canadian Minister of State for Western Economic Diversification, announced funding of $5.5 million which will allow TRIUMF to acquire the new cyclotron as well as …

Richmond, BC, October 25, 2012 – Advanced Cyclotron Systems Inc. (“ACSI”) of Richmond, British Columbia, announces a new product for the medical imaging sector. This new product, called CYCLOTEC™, is the medical isotope technetium-99m (“Tc-99m”) that is produced in cyclotrons using ACSI’s exclusive target irradiation hardware system.

Richmond, BC, October 25, 2012 – Advanced Cyclotron Systems Inc. (“ACSI”) announces that the first TR-24 cyclotron has been installed and successfully commissioned at the Centre Hospitalier Universitaire de Sherbrooke (“CHUS”) in Quebec, Canada. This cyclotron has been successfully commissioned to achieve 500µA at 24 MeV energy. The TR-24 is also the first cyclotron in the world designed to produce commercial quantities of CycloTec™. CycloTec™ is Technetium 99 (“Tc-99m”) produced on ACSI’s cyclotrons.

Richmond, BC, September 26, 2012 – Advanced Cyclotron Systems Inc. (“ACSI”) is pleased to announce the opening of a new office in Frankfurt, Germany. The new office, Advanced Cyclotron Systems GmbH (“ACSI GmbH”), is the Company’s first office expansion into Europe and currently serves Europe, the Middle East, and Russia.

The most commonly-used medical isotope, technetium-99m (99mTc) (half-life 6 hours), is derived from its parent, molybdenum-99 (99Mo) (half-life 2.7 days), which is currently produced in a few aging nuclear reactors. This supply chain is becoming increasingly fragile and when a major reactor is removed from service unexpectedly or for planned maintenance, a world-wide medical isotope shortage may result.